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Oral squamous cell carcinoma (OSCC) is diagnosed in 30,000 Americans every year. If detected 
and treated early with surgery or radiation, five-year survival is greater than 50% for OSCC localized 
to the tongue, floor of the mouth, or lips. If metastases are detected in neck lymph nodes, OSCC 
five-year survival decreases by 50%. Furthermore, therapies for advanced disease can lead to life-
long swallowing and speech impairments. By understanding the underlying molecular mechanism of 
tumor progression, novel targeted therapies could be developed for OSCC. In the first study to 
characterize the genomic aberrations in metastatic tumor cells, Staff Scientist Dr. Chang Xu and 
Assistant Member Dr. Eduardo Méndez from the Clinical Research Division identified biomarkers for 
OSCC progression and potential therapeutic targets by analyzing gene changes associated with 
metastatic versus non-metastatic OSCC primary tumors. 
To identify molecular differences between primary and metastatic OSCC, DNA copy number 
changes were correlated with gene expression changes using DNA and RNA arrays (see figure). A 
signature of 95 genes was identified in tumor cells from lymph node metastases (n=20) compared to 
non-metastatic primary tumors (n=17). These genes were associated with survival and prognosis of 
patients by looking at an independent set of 133 OSCC patients, where 65 patients were still alive at 
the end of the follow up time (mean: 5.4 years, range 4.0-7.3 years). Using the gene signature and 
hierarchical clustering based on the gene expression variances determined by principal component 
analysis, patients were divided into two clusters that correlated with the stage of disease and 
prognosis. The 5-year overall survival for patients in cluster 1, who had mainly primary tumors, was 
higher than patients in cluster 2, who were more likely to have nodal metastasis 
(69.1±6.98% versus41.7±5.45%, P = 0.000858). Using multivariate analysis adjusting for sex, stage, 
age, and human papillomavirus (HPV) status, hazard ratios (HR) for cluster 2 patients were 3.45 
(95% confidence interval: 1.84-6.50) for overall survival and 4.75 (95% confidence interval: 2.03-
11.11) for OSCC-specific mortality. 
Next, the authors examined if the genes unique to metastases also affected tumor growth. They 
established three OSCC cell lines from metastatic tumors, and two derived from early-stage primary 
tumors. The metastasis derived cell lines displayed a more aggressive phenotype in vitro and in 
vivo. Finally, 26 of the 95 transcripts with amplification and overexpression were silenced by RNA 
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interference in the five OSCC cell lines. In at least one of the OSCC cell lines, 18 of the 26 genes 
(69%) reduced    cell viability. On average, the early-stage OSCC cell lines were more sensitive to 
gene silencing. However, silencing expression of the gene GAP SH3 Binding Protein 1 (G3BP1) 
decreased cell viability and increased apoptosis in late-stage OSCC. Upon further characterization, 
the induction of cell death by G3BP1 silencing preferentially occurred in OSCC cell lines that also 
had a mutation in the tumor suppressor p53. The precise mechanism for why knockdown of G3BP1 
expression induces cell death remains to be elucidated. Nevertheless, G3BP1 was identified as a 
novel therapeutic target previously not described for head and neck cancer. 
According to Dr. Méndez, this study provides “a roadmap showing which genes may be essential for 
the survival advantage inherent in metastatic tumor cells, and this can be exploited to selectively 
target these cells.” Efforts are underway to develop the identified gene signature as a prognostic 
biomarker for OSCC, as well as to understand how these genes mediate metastasis and 
proliferation. Based of the current study, Dr. Méndez was awarded a $720,000 four-year Research 
Scholar Grant from the American Cancer Society to further study potential therapeutic targets in 
OSCC. 
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Image adapted from manuscript, published in the open-
access journal PLOS Genetics. 
 
 
A signature of 95 genes differentially 
expressed between early-stage primary 
OSCC tumors and late-stage metastatic 
tumors was identified correlating gene 
expression changes with DNA copy 
number changes. Heat-map of 1,988 
transcripts with differential expression 
between primary tumors (yellow) and 
metastatic tumors isolated from lymph 
nodes (red) as determined by mRNA 
expression arrays (top panel). DNA copy 
number differences between primary 
and metastatic OSCC were determined 
by single-nucleotide polymorphism 
arrays. Red bars highlight genes with 
significant Z-score DNA copy number 
differences (bottom panel, top). The 
correlation coefficients of copy number 
changes and gene expression are show 
by Manhattan plot (bottom panel, 
bottom). Each dot represents one of the 
differentially expressed genes, with 
significant genes highlighted in red. 
